source
- PTC Therapeutics agrees to pay up to $211 million for Sangamo’s experimental Fabry disease gene therapyPTC Therapeutics announced it will invest up to $211 million to acquire rights to an advanced gene therapy for Fabry disease being developed by Sangamo Therapeutics. The therapy, called ST-920 (is…
- Baxter recalls Duo-Vent IV solution sets over risk of air bubbles in patientsBaxter has issued a recall of its Duo-Vent solution sets and male Luer lock adapters after the FDA identified a risk that the devices could contain air bubbles in the drip chamber and tubing. The…